At the recent Pharma Partnering EU Summit in Basel, Switzerland, global business development, licensing (BD&L), and investment leaders gathered to negotiate the next wave of high-stakes biopharma deals. With asset failure carrying a devastating financial toll, Intelligencia AI connected with senior decision-makers to demonstrate how our purpose-built machine learning ecosystems completely remove legacy guesswork from asset valuation. By delivering objective, data-driven assessments of a drug’s probability of technical and regulatory success (PTRS), our predictive analytics platform empowers cross-functional teams to fearlessly de-risk M&A due diligence, isolate high-value molecules, and confidently protect corporate value during intense partnering trade-offs.
